Skip to content

FIBRONEER-ON: Extension Trial for IPF

Search Clinical Trials

Trial Objectives


Continuous scarring (fibrosis) can gradually impair lung function, leading to breathing difficulties. Researchers are examining how an investigational medication called BI 1015550 can help adults with progressive lung diseases with fibrosis in a follow-up to the international FIBRONEER clinical trials.

Participants in this study will be given BI 1015550 whether or not they received the treatment or a placebo (a medication with no active ingredient) in the previous phases of the trial. All participants will receive lung function testing to determine what dose of the treatment is most effective for their symptoms. This data will help researchers determine how effective and safe this treatment is in a longer term than the original study.
 

Who Can Participate


Patients who previously completed treatment in the FIBRONEER-IPF or FIBRONEER-ILD studies. Enrollment is closed.

Age: Not Specified Gender: Any

Estimated Time Commitment


Up to 99 weeks

Payment & Reimbursement


Payment: Provided

Travel Reimbursement: Available

Trial Contact


For more information, contact:

K-Fier-140.jpg
Kaitlin Fier
303.270.2852

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Boehringer Ingelheim

Principal Investigators

Jeff Swigris

Jeff Swigris, DO, MS